
Diabetes mellitus is a major source of morbidity in
developed countries. Among its co-morbid conditions, atherosclerosis
is perhaps the most important. Since the availability of insulin, up to
three-quarters of all deaths among diabetics can be directly attributed to
coronary artery disease (CAD). In patients with IDDM, up to one third will
die of CAD by the age of 50 years. A number of known risk factors for CAD,
such as hypertension, central obesity and dyslipidemia, are more common in
diabetics than in the general population.
Thus diabetes represents a major contributing factor to
the CAD burden in the developed world, and most of the excess attributed
risk of CAD in diabetics cannot be readily quantified with the use of
traditional risk factors analysis.
Diabetes is associated with a variety of metabolic
abnormalities, principle among which is hyperglycaemia. The relation between
hyperglycaemia and CAD is the subject of considerable debate because serum
glucose does not consistently predict the existence of CAD. Presumably, this
confusion sterns from the reliance on a simple blood glucose measurement, as
recent prospective data have clearly established a link between a marker for
chronic average glucose levels (HbA1c) and cardiovascular morbidity and
mortality.
There is a considerable controversy with respect to the
precise mechanism by which hyperglycaemia may contribute to the development
of CAD in diabetes. There are established sequelae of hyperglycaemia, such
as cytotoxicity, increased extracellular matrix production and vascular
dysfunction and have all been implicated in the pathogenesis of
diabetes–induced vascular disease.
Excess oxidative stress has captured considerable
attention as a potential mechanism for the increased vascular disease in
diabetics. The established association between atherosclerosis and lipid
peroxidation within the vascular wall has led to a renewed interest in the
oxidative stress of hyperglycaemia as a potential mechanism for diabetic
vascular disease (Figure 1).
The molecular mechanism of biological oxidation by glucose was first identified in 1912 by Louis Maillard. This French chemist described a brown colour that formed from heating solutions of carbohydrates and amines and termed this process the “réaction du Maillard”. The reaction involves the combination of the aldehyde group of glucose with the amine group on proteins to form a Schiff-base followed by a rearrangement to form fructoselysine.
Figure 1. Hyperglycemic induced oxidative sress
|
This reversible glycosylation of aminogroups, or
glycation, underlies the formation of HbA1c, the well-recognized marker of
chronic glycaemic control in diabetes mellitus, but is not of any direct
pathophysiological significance for the complications of diabetes. The final
stage of the Maillard reaction involves the irreversible oxidation, or
glucoxidation of fructoselysine to yield a host of advanced glycation
end-products (AGEs) such as carboxymethyl-lysine, pentosidine and pyrroline,
the formation of which correlate directly with the vascular and renal
complications of diabetes mellitus. Unlike the quantitation of AGEs and
AGE-modified proteins, the quantitation of lipid peroxidation in the setting
of hyperglycaemia has been more problematic.
A novel class of prostanoid-like compounds, known
collectively as F2-isoprostanes are specific non-enzymatic oxidation
products of arachidonic acid and are subsequently released in the free form
through the action of phospholipases.
In the quantification of oxidative stress, the
determination of F2-isoprostanes has proved quite useful as a marker of
lipid peroxidation both in vitro and in vivo. However the precise role of
enhanced lipid peroxidation, and F2-isoprostanes in particular, in the
vascular pathology associated with diabetes mellitus remains to be
determined.
The simultaneous increased levels of 8-epi PGF2a in
plasma and in urine of NIDDM and in IDDM as well tends to implicate
hyperglycaemia as the culprit of metabolic derangement, since this is a
major common feature of both patient populations. Improved glycaemic control
reduces vascular oxidative stress, and has a profound influence on the
degree of oxidative stress in diabetic patients.
In addition to AGE formation by oxidation of
fructoselysine, there are other putative mechanisms that link hyperglycaemia
to oxidative stress. The most direct is the auto-oxidation of glucose, which
is subject to ene-diol rearrangement that results in the formation of an
ene-diol radical ion. This species is capable to reduce molecular oxygen to
form superoxide anion, which may contribute to the oxidation of lipids or to
the activation of platelets. The dicarbonyl products are quite reactive and
modify adjacent lysine groups to form AGEs such as n-(carboxymethyl)lysine.
These reactions derived from glycose enolization are dependent on transition
metal ions, and the availability of free, redox-active transition metal ions
in vivo is controversial. Recent data demonstrating glycation-induced
ceruloplasmin fragmentation and free copper release offer one possible
mechanism for a source of extracellular transition metals. As an alternative
mechanism of AGE-mediated oxidative stress, AGEs have also been shown to
induce cellular lipid peroxidation through interacting with their specific
surface receptor, and this effect can be attenuated by vitamin E.
Although there is a considerable evidence for increased
lipid peroxidation in diabetes, arguments for a more generalized increase in
oxidative stress are not secure. In vitro glycoxidation of collagen results
in formation of AGEs as well as the protein oxidation products o-tyrosine
and methionine sulphoxide. Diabetic patients demonstrate an increase in AGE
formation compared with age-matched control subjects but no increase in the
non-carbohydrate-derived protein oxidation products o-tyrosine and
methionine sulphoxide. These data underscore the need for further
investigation in to the precise molecular nature of oxidative stress in
diabetes mellitus and the impact of such stress on diabetic vascular
complications.
Patients with diabetes mellitus are particularly susceptible to morbidity and mortality resulting from cardiovascular diseases, especially atherosclerosis. Diabetes and coronary heart disease share many of the same risk factors, such as disorders of lipid metabolism and hypertension. The oxidation of low density lipoproteins (LDL) is considered a key event in the initiation of atherosclerosis. Although the exact mechanisms responsible for accelerated atherogenesis in patients with diabetes are not completely understood, an important role may be played by increased glycolisation of lipoproteins. Lipid abnormalities in diabetic patients are presented in Figure 2.
Figure 2. Lipid abnormalities in diabetic patients
The major aim of the study was to evaluate oxidative stress in well controlled type I diabetes without clinical complications. 36 patients, 19 males and 17 females were taken up in the protocol, aged 30 ± 9.7 years with 12.9 ± 6.8 years disease duration. Exclusion criteria for hypertension, vitamin supplementation or hypolipidaemic agents were applied. A control group of 37 persons, 15 males and 22 females, sex and age matched, without lipid abnormalities were compared. Besides basic biochemical analyses, more specific oxidative stress parameters were examined, as lag phase, TBARS and quanitation of ox-LDL with a monoclonal antibody (mAb-4EG) on ELISA. The major events were the differences in the serum lag phase between men and women (Figure 3), more pronounced in the diabetic patients and were significantly correlated to differences in plasma copper and uric acid concentrations (Figure 4).
Figure 3. Differences in the serum lag phase between man
and woman
|
|
Figure 4. Relation oxidative stress and anti-oxidants in
IDDM
There was a direct relationship between the plasma lipid composition, ox-LDL
and lag phase. A reciprocal value was obtained with the HDL value and the
lag phase, probably due to changes in para-oxidase activity. There was no
measured influence of serum vitamins on the oxidative stress parameters. The
study conclusions were as follows:
There are significant differences in the lagphase between the
control group and the well controlled IDDM patients.
There is a gender influence: females show a shorter lagphase against
men, as well in the control group as in Type-I diabetics.
Between LDL-C, lagphase and the oxidation rate a significant
correlation was observed. Similar findings were gained on LDL in vitro,
although there was no positive realtionship with a-tocopherol.
HDL has a reciprocal value against the lagphase (r2 =
0.38), explained by the high concentrations of lipidhydroperoxydes/HDL
particle and the low con-centration of lipophilic antioxidants. HDLox
> LDLox ?
The protective effect of HDL on LDLoxidation is determined by the
paroxanase concentration, which is decreased in diabetic patient. LCAT
and PAF-AH demonstrate similar protection.
OxLDL has a positive correlation with LDL-C and a negative one with HDL-C.
Lagphase and vitamin E are not correlated, there is a negative
correlation between Vit. E/LDL and lagphase and no correlation between
a-tocopherolquinone/LDL and oxLDL.
Astley S, Langrish-Smith A, Southon S, Sampson M. Vitamin E
supplementation and oxidative damage to DNA and plasma LDL in type 1
diabetes. Diabetes Care 1999;22(10):1626-31.
Ruiz C, Alegria A, Barbera R, Farre R, Lagarda MJ. Lipid
peroxidation and antioxidant enzyme activities in patients with type 1
diabetes mellitus. Scand J Clin Lab Invest 1999;59(2):99-105.
Ashour et al. Children type I - diabetes and chronic
hyperglycaemia have a decreased antioxidant defense mechanism. J Clin
Biochem Nutr 1999;26:99.
Maxwell et al. Predisposition of type I - diabetes to
atherosclerosis is not determined by the anti-oxidative activity.
Atherosclerosis 1997;89-96.
Tsai et al. Lagphase of LDL in type I - diabetes is lower
than in controls. Diabetes 1994;1010-4.
